Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:antigen |
gptkb:CD19
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Juno_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
JCAR014
|
| gptkbp:mechanismOfAction |
genetically engineered T cells to target CD19-positive cells
|
| gptkbp:relatedTo |
immunotherapy
gene therapy |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:usedFor |
leukemia
B-cell malignancies |
| gptkbp:bfsParent |
gptkb:Juno_Therapeutics
|
| gptkbp:bfsLayer |
5
|